Literature DB >> 26581141

Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort.

Daniel M Trifiletti1, Samuel Swisher-McClure2, Timothy N Showalter1, Sarah E Hegarty3, Surbhi Grover4.   

Abstract

PURPOSE: To review the National Cancer Database (NCDB) to evaluate postoperative high-risk cervical cancer patients for factors associated with a benefit from chemoradiation therapy (CRT) over external beam radiation therapy alone (EBRT). METHODS AND MATERIALS: The National Cancer Database was queried for women with cervical cancer treated with hysterectomy and adjuvant EBRT from 2002 to 2012. Only patients with pathologic lymph node involvement (LN+), positive surgical margins, and/or parametrial invasion were included in our analysis (on the basis of Peter's criteria). Univariable and multivariable analyses (MVA) were performed, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to investigate for factors associated with of CRT utilization and overall survival (OS).
RESULTS: A total of 3053 patients met inclusion criteria, and 2479 received adjuvant CRT (81%), whereas 574 (19%) received EBRT alone. Factors associated with increased CRT utilization on MVA included age <69 years, year of diagnosis ≥2008, non-adenocarcinoma histology, and LN+. Use of CRT improved OS among the entire cohort on MVA (HR 0.76, CI 0.601-0.962; P=.022). On MVA, CRT improved OS in patients with LN+ as their sole Peter's criteria (HR 0.58, CI 0.413-0.814; P=.002). Chemoradiation therapy did not improve OS in patients with only positive margins (P=.73), only parametrial invasion (P=.95), or any combination of these 2 factors without LN+ (P=.63).
CONCLUSIONS: The use of adjuvant CRT after hysterectomy improves OS in patients with high-risk cervical cancer compared with EBRT alone, but this benefit seems to be restricted to patients with LN+. The benefits of adjuvant CRT over EBRT alone in patients with parametrial invasion and/or positive margins (without nodal involvement) are unknown.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26581141     DOI: 10.1016/j.ijrobp.2015.09.001

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Young-Taek Oh; Seung Hee Kang
Journal:  BMC Cancer       Date:  2017-04-28       Impact factor: 4.430

2.  The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement.

Authors:  Yongrui Bai; Ling Rong; Bin Hu; Xiumei Ma; Jiahui Wang; Haiyan Chen
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

Review 3.  Major clinical research advances in gynecologic cancer in 2021.

Authors:  Jeong-Yeol Park; Jung-Yun Lee; Yoo-Young Lee; Seung-Hyuk Shim; Dong Hoon Suh; Jae-Weon Kim
Journal:  J Gynecol Oncol       Date:  2022-03       Impact factor: 4.401

4.  Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer.

Authors:  Eva Meixner; Line Hoeltgen; Philipp Hoegen; Laila König; Nathalie Arians; Laura L Michel; Katharina Smetanay; Carlo Fremd; Andreas Schneeweiss; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  The Selection of Time Interval Between Surgery and Adjuvant Therapy in Early Stage Cervical Cancer.

Authors:  Kai-Yun You; Xin-Hui Zhou; Yan-Hui Jiang; Zhuo-Fei Bi; Yi-Min Liu; Xing-Sheng Qiu
Journal:  Int J Gynecol Cancer       Date:  2018-09       Impact factor: 3.437

6.  Risk Stratification of Early-Stage Cervical Cancer with Intermediate-Risk Factors: Model Development and Validation Based on Machine Learning Algorithm.

Authors:  Ran Chu; Yue Zhang; Xu Qiao; Lin Xie; Wei Chen; Ying Zhao; Yintao Xu; Zeng Yuan; Xiaolin Liu; Aijun Yin; Zhiwen Wang; Qing Zhang; Xingsheng Yang; Xuantao Su; Beihua Kong; Kun Song
Journal:  Oncologist       Date:  2021-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.